GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Sale Of Investment

KalVista Pharmaceuticals (STU:4XC1) Sale Of Investment : €109.23 Mil (TTM As of Jan. 2025)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Sale Of Investment?

KalVista Pharmaceuticals's sale of investment for the three months ended in Jan. 2025 was €14.69 Mil. It means KalVista Pharmaceuticals gained €14.69 Mil from selling investments. KalVista Pharmaceuticals's sale of investment for the trailing twelve months (TTM) ended in Jan. 2025 was €109.23 Mil.

Compared with last quarter (€44.87 Mil in Oct. 2024 ), KalVista Pharmaceuticals gained less money from selling investments in Jan. 2025 (€14.69 Mil).


KalVista Pharmaceuticals Sale Of Investment Historical Data

The historical data trend for KalVista Pharmaceuticals's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Sale Of Investment Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.43 44.84 181.23 128.46 97.82

KalVista Pharmaceuticals Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.61 14.43 35.25 44.87 14.69

KalVista Pharmaceuticals Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €109.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


KalVista Pharmaceuticals Sale Of Investment Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines